Wuhan Hiteck Biological Pharma Co Ltd Cash Flow Conversion Efficiency
Wuhan Hiteck Biological Pharma Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Wuhan Hiteck Biological Pharma Co Ltd (300683) has a cash flow conversion efficiency ratio of -0.008x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-17.49 Million ≈ $-2.56 Million USD) by net assets (CN¥2.24 Billion ≈ $328.35 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Wuhan Hiteck Biological Pharma Co Ltd (2013–2025)
Cash flow conversion efficiency of Wuhan Hiteck Biological Pharma Co Ltd from 2013 to 2025. This chart illustrates how Wuhan Hiteck Biological Pharma Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Wuhan Hiteck Biological Pharma Co Ltd (300683) stock price for real-time trading data and today's change.
Wuhan Hiteck Biological Pharma Co Ltd Cash Flow Conversion Ratio Explained
Wuhan Hiteck Biological Pharma Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Wuhan Hiteck Biological Pharma Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Wuhan Hiteck Biological Pharma Co Ltd ranked by their cash flow conversion efficiency. Also see Wuhan Hiteck Biological Pharma Co Ltd market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lungteh Shipbldg Co Ltd
TW:6753
|
-0.162x |
|
Intrepid Potash Inc
NYSE:IPI
|
0.067x |
|
RADIANCE HLDGS GRP.HD-01
F:RDH
|
N/A |
|
Bandwidth Inc
NASDAQ:BAND
|
0.057x |
|
Beijing Emerging Eastern Aviation Equipment Co Ltd Class A
SHE:002933
|
0.009x |
|
Citi Trends Inc
NASDAQ:CTRN
|
0.167x |
|
Jasmine International Public Company Limited
BK:JAS-R
|
0.050x |
|
Napatech A/S
OL:NAPA
|
-0.214x |
Annual Cash Flow Conversion Efficiency for Wuhan Hiteck Biological Pharma Co Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of Wuhan Hiteck Biological Pharma Co Ltd from 2013 to 2025. Review Wuhan Hiteck Biological Pharma Co Ltd free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.17 Billion ≈ $317.45 Million |
CN¥-76.54 Million ≈ $-11.20 Million |
-0.035x | -475.05% |
| 2024-12-31 | CN¥2.41 Billion ≈ $352.89 Million |
CN¥22.69 Million ≈ $3.32 Million |
0.009x | +341.74% |
| 2023-12-31 | CN¥2.50 Billion ≈ $365.17 Million |
CN¥5.31 Million ≈ $777.64K |
0.002x | -90.62% |
| 2022-12-31 | CN¥2.34 Billion ≈ $341.71 Million |
CN¥53.03 Million ≈ $7.76 Million |
0.023x | +340.20% |
| 2021-12-31 | CN¥2.34 Billion ≈ $342.86 Million |
CN¥12.09 Million ≈ $1.77 Million |
0.005x | +145.17% |
| 2020-12-31 | CN¥1.72 Billion ≈ $252.41 Million |
CN¥-19.70 Million ≈ $-2.88 Million |
-0.011x | -131.90% |
| 2019-12-31 | CN¥1.76 Billion ≈ $257.61 Million |
CN¥63.03 Million ≈ $9.22 Million |
0.036x | -16.64% |
| 2018-12-31 | CN¥1.71 Billion ≈ $250.17 Million |
CN¥73.42 Million ≈ $10.74 Million |
0.043x | -15.06% |
| 2017-12-31 | CN¥1.64 Billion ≈ $240.44 Million |
CN¥83.08 Million ≈ $12.16 Million |
0.051x | -75.28% |
| 2016-12-31 | CN¥703.35 Million ≈ $102.92 Million |
CN¥143.86 Million ≈ $21.05 Million |
0.205x | -23.66% |
| 2015-12-31 | CN¥596.76 Million ≈ $87.32 Million |
CN¥159.89 Million ≈ $23.40 Million |
0.268x | +6.18% |
| 2014-12-31 | CN¥536.59 Million ≈ $78.52 Million |
CN¥135.40 Million ≈ $19.81 Million |
0.252x | -16.35% |
| 2013-12-31 | CN¥254.64 Million ≈ $37.26 Million |
CN¥76.82 Million ≈ $11.24 Million |
0.302x | -- |
About Wuhan Hiteck Biological Pharma Co Ltd
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the production and sales of bioengineering products and lyophilized powder injections in China and internationally. The company operates through Biopharmaceutical Division; Pharmaceutical Technology Services Division; In Vitro Diagnostic Reagents Division; Production and Sales Division of Active Pharmaceutical Ingredi… Read more